Intellia Therapeutics Inc.

$70.45 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Join the waitlist

About Intellia Therapeutics Inc.

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.

Stock Analysis

last close $74.77
1-mo return 9.9%
3-mo return -8.7%
avg daily vol. 1.36M
52-week high 92
52-week low 12.32
market cap. $4.8B
forward pe -
annual div. -
roe -33.7%
ltg forecast -
dividend yield -
annual rev. $58M
inst own. 82.9%
baraka

Join the waitlist for early access and a chance to earn $50 in free stock

Join the waitlist